June 2, 2019 / 4:35 PM / 4 months ago

BRIEF-Aduro Biotech And Novartis Present Results From Ongoing Phase 1B Study

June 2 (Reuters) - Aduro Biotech Inc:

* ADURO BIOTECH AND NOVARTIS PRESENT RESULTS FROM ONGOING PHASE 1B STUDY OF STING AGONIST ADU-S100 (MIW815) IN COMBINATION WITH ANTI-PD-1 MONOCLONAL ANTIBODY SPARTALIZUMAB (PDR001) IN PATIENTS WITH ADVANCED SOLID TUMORS OR LYMPHOMAS

* ADURO BIOTECH- AS OF APRIL 5, FIVE PATIENTS TREATED IN WEEKLY DOSING SCHEDULE GROUP ACHIEVED CONFIRMED RESPONSES, ONE OF WHICH WAS COMPLETE RESPONSE Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below